Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab versus Omalizumab in severe CRSwNP with comorbid asthma
NCT04998604Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 4, randomised, double-blind trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Sanofi. Primary endpoints: Nasal Polyp Score at 24 weeks and University of Pennsylvania Smell Identification Test at 24 weeks. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT04998604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998604.